CClinicalTrials.gg
CompletedNCT01216709MJAUUpdated Mar 26, 2020

Iron Absorption From Infant Formula and Iron Drops in Infants (MJAU-studien)

An interventional study of ferrous sulfate and iron-fortified infant formula (12.4 mg iron/L) in Infant, Dietary Supplements and Food, Fortified, sponsored by Umeå University. Completed at 1 site in Sweden. Open to participants aged 6 Months to 7 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-26.

Sponsored by Umeå University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
6 Months to 7 Months
Sex
All
01

Study summary

Iron deficiency (ID) affects up to 25% of Swedish infants and severe ID is associated with cognitive and behavioral problems. To avoid this, iron supplements or iron-fortified infant foods are recommended for infants. However, the optimal iron dose and mode of delivery have not yet been established. This is a concern as excessive iron intake may impair growth and increase morbidity in iron-sufficient infants. Previous studies have suggested that iron-fortified foods may have different effects than iron supplements. In this study, the investigators will investigate whether the mode of iron administration (supplementation vs. fortification) and the amount consumed (high intakes vs. low intakes) affect iron absorption, iron utilization, and zinc absorption in healthy term non-iron-deficient 6-month-old infants.

02

Conditions studied

  • Infant
  • Dietary Supplements
  • Food, Fortified

Keywords

  • Infant
  • Dietary Supplements
  • Food, Fortified
  • Iron Absorption
03

In context

Lead sponsor

Umeå University is the lead sponsor of 263 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 7 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 6-7 months of age at the start of intervention
  • healthy at enrollment
  • full-term (>37 gestational weeks at birth)
  • birth weight >2500 g
  • predominantly bottle-fed at recruitment

Exclusion criteria

Exclusion Criteria:

  • iron deficiency at enrollment
  • previous or current use of iron supplements
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    iron drops

    Dietary Supplement: ferrous sulfate

  • Experimental
    iron-fortified formula (2.3 mg iron/L)

    Other: iron-fortified infant formula (2.3 mg iron/L)

  • Experimental
    iron-fortified formula (12.4 mg iron /L)

    Other: iron-fortified infant formula (12.4 mg iron/L)

Interventions

  • Dietary supplementferrous sulfate

    6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days

  • Otheriron-fortified infant formula (12.4 mg iron/L)

    6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days

  • Otheriron-fortified infant formula (2.3 mg iron/L)

    1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days

06

What researchers measure

Primary outcomes

  1. iron absorption

    Time frame: 1 month after enrollment

Secondary outcomes

  1. indicators of iron metabolism, growth, and oxidative stress

    Time frame: 1 month and 1.5 months after enrollment

  2. zinc absorption

    Time frame: 1 month after enrollment

07

Study locations

1 site
  • Department of Clinical Sciences, Pediatrics, Umeå University Hospital
    Umeå, 901 85, Sweden
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01216709
Lead sponsor
Umeå University
Collaborators
Swiss Federal Institute of Technology, University of California, Davis
Responsible party
Magnus Domellöf (MD, PhD, Umeå University) — Principal investigator
First posted
Oct 7, 2010
Start date
Oct 2010
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Mar 26, 2020

Study contacts

Magnus Domellöf, MD, PhD
principal investigator · Umeå University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion